We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
-3.68%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$982M
AUM Growth
+$92.9M
(+10%)
Cap. Flow
+$134M
Cap. Flow
% of AUM
13.65%
Top 10 Holdings %
Top 10 Hldgs %
4.69%
Holding
1,940
New
653
Increased
414
Reduced
285
Closed
576
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OPLN
Openlane
OPLN
|
+$4.73M |
| 2 |
BridgeBio Pharma
BBIO
|
+$4.54M |
| 3 |
Suburban Propane Partners
SPH
|
+$3.95M |
| 4 |
Morgan Stanley
MS
|
+$3.93M |
| 5 |
Kulicke & Soffa
KLIC
|
+$3.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$4.61M |
| 2 |
Domino's
DPZ
|
+$3.96M |
| 3 |
Bruker
BRKR
|
+$3.65M |
| 4 |
TJX Companies
TJX
|
+$3.62M |
| 5 |
Starbucks
SBUX
|
+$3.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.3% |
| 2 | Industrials | 16.2% |
| 3 | Technology | 12.7% |
| 4 | Financials | 11.7% |
| 5 | Consumer Discretionary | 9.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Wave Life Sciences
WVE
$1.2B
| $161K | 0.02% |
+32,769
| New | +$199K |
|
1277
Plains All American Pipeline
PAA
$16.1B
| $160K | 0.02% |
+15,741
| New | +$156K |
|
|
ORC
1278
Orchid Island Capital
ORC
$1.31B
| $156K | 0.02% |
6,390
-1,059
| -14% | -$26.7K |
|
1279
Precigen
PGEN
$2.59B
| $156K | 0.02% |
+31,346
| New | +$180K |
|
|
IMGN
1280
DELISTED
Immunogen Inc
IMGN
| $154K | 0.02% |
+27,240
| New | +$157K |
|
1281
Forte Biosciences
FBRX
$1.57B
| $152K | 0.02% |
+2,051
| New | +$1.14M |
|
|
LITS
1282
Lite Strategy Inc
LITS
$30.9M
| $152K | 0.02% |
2,755
+1,370
| +99% | +$75.4K |
|
1283
Nexa Resources
NEXA
$1.87B
| $152K | 0.02% |
+20,039
| New | +$160K |
|
|
TTOO
1284
DELISTED
T2 Biosystems, Inc
TTOO
| $152K | 0.02% |
+33
| New | +$166K |
|
|
DCH
1285
Dauch Corp
DCH
$1.51B
| $147K | 0.02% |
16,710
-59,188
| -78% | -$542K |
|
1286
Kearny Financial
KRNY
$599M
| $146K | 0.01% |
+11,774
| New | +$145K |
|
|
DESP
1287
DELISTED
Despegar.com
DESP
| $144K | 0.01% |
+11,965
| New | +$147K |
|
1288
KORU Medical Systems
KRMD
$164M
| $144K | 0.01% |
+50,690
| New | +$168K |
|
1289
Yext
YEXT
$574M
| $143K | 0.01% |
11,898
-62,302
| -84% | -$803K |
|
|
ZYNE
1290
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $143K | 0.01% |
+33,788
| New | +$151K |
|
1291
Intellicheck
IDN
$79.6M
| $142K | 0.01% |
+17,369
| New | +$147K |
|
|
ALNA
1292
DELISTED
Allena Pharmaceuticals
ALNA
| $138K | 0.01% |
+152,731
| New | +$150K |
|
1293
ADT
ADT
$5.58B
| $136K | 0.01% |
+16,750
| New | +$154K |
|
|
CANO
1294
DELISTED
Cano Health, Inc.
CANO
| $135K | 0.01% |
+106
| New | +$128K |
|
|
BTRS
1295
DELISTED
BTRS Holdings Inc. Class 1 Common Stock
BTRS
| $135K | 0.01% |
12,701
-13,573
| -52% | -$157K |
|
1296
Gossamer Bio
GOSS
$87M
| $133K | 0.01% |
+10,578
| New | +$97.4K |
|
|
KNDI
1297
Kandi Technologies Group
KNDI
$65.5M
| $133K | 0.01% |
+29,854
| New | +$151K |
|
|
ENBL
1298
DELISTED
ENABLE MIDSTREAM PARTNERS, LP
ENBL
| $133K | 0.01% |
+16,357
| New | +$134K |
|
|
TUYA
1299
Tuya Inc
TUYA
$1.1B
| $132K | 0.01% |
+14,551
| New | +$224K |
|
1300
Kinross Gold
KGC
$32.8B
| $131K | 0.01% |
24,428
-5,842
| -19% | -$35K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q3 2021 Portfolio in Review
As of Q3 2021, GSA Capital Partners held 1,940 positions worth $982M, up 10% from $889M the previous quarter. Its ten largest holdings account for 4.7% of the portfolio.
GSA Capital Partners deployed $134M of net new capital in Q3 2021, opening 653 new positions and adding to 414 existing holdings. Its largest new stake was Openlane: 280,405 shares worth $4.6M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 15% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Amazon, an estimated $4.61M trimmed.
- GSA Capital Partners's largest Q3 2021 buy was Openlane: 280,405 shares worth $4.6M.
- GSA Capital Partners added most to BridgeBio Pharma in Q3 2021, an estimated $4.54M increase.
- GSA Capital Partners's biggest Q3 2021 reduction was Amazon, cutting an estimated $4.61M.
- GSA Capital Partners fully exited TJX Companies in Q3 2021, selling an estimated $3.62M.
- GSA Capital Partners's ten largest holdings make up 4.7% of its $982M portfolio in Q3 2021.
- GSA Capital Partners opened 653 new positions and closed 576 in Q3 2021.
- GSA Capital Partners's portfolio value rose 10% quarter-over-quarter to $982M.
Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.